Compare
Kesimpta vs. Briumvi

Kesimpta (ofatumumab) is an injectable medication for adults with relapsing forms of multiple sclerosis (MS). It works as a monoclonal antibody to help lessen MS flare-ups that come and go. Kesimpta (ofatumumab) is injected under the skin. You can use the Kesimpta prefilled syringes or Sensoready Pens to inject. After the first 3 weekly injections, you inject the medication once a month. Some common side effects include a higher risk of infections, pain or swelling at the injection site, and headache.

• Relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS, clinically isolated syndrome, and secondary progressive MS

• Upper respiratory tract infections (39%)
• Reactions related to the injection (e.g., fever, chills, tiredness; 21%)
• Headache (13%)
• Reaction at the injection site (e.g., pain, redness, swelling; 11%)
• Urinary tract infection (10%)

• Risk of infections
• Injection reactions
• Lower antibody levels
• Harm to an unborn baby

Briumvi (ublituximab or ublituximab-xiiy) is a medication used to treat relapsing forms of multiple sclerosis (MS). This medication is given as an infusion into your veins by a healthcare provider. After you finish the starting doses, you'll receive Briumvi (ublituximab) once every 6 months. Briumvi (ublituximab) can raise your risk for infusion-related reactions so your provider might give you pre-medications, such as a corticosteroid, before your infusion to lower the risk of these reactions.

• Relapsing forms of multiple sclerosis (MS)

• Fever, chills, headaches, and other infusion-related reactions (48%)
• Runny nose, sore throat, and other symptoms of upper respiratory tract infections (45%)
• Cough, chest pain, and other symptoms of lower respiratory tract infections (9%)

• Infusion reactions
• Risk of infections
• Low antibodies
• Potential harm to unborn babies